Journal Mobile Options
Table of Contents
Vol. 22, No. 1, 2006
Issue release date: June 2006
Dement Geriatr Cogn Disord 2006;22:73–82

Apolipoprotein E ε4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer’s Disease: Retrospective and Prospective Analysis

Kleiman T. · Zdanys K. · Black B. · Rightmer T. · Grey M. · Garman K. · MacAvoy M. · Gelernter J. · van Dyck C.
aAlzheimer’s Disease Research Unit; bDivision of Molecular Psychiatry, Department of Psychiatry, and cDepartment of Neurobiology, Yale University School of Medicine, New Haven, Conn., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: The apolipoprotein E (ApoE) ε4 allele is a well-documented genetic risk factor for Alzheimer’s disease (AD). Its role, if any, in the progression of cognitive and functional impairment in AD has been the subject of discrepant reports in the literature. This study aimed to determine whether ApoE ε4 dose is related to the progression of cognitive and functional decline in AD patients by combined retrospective and prospective analyses. Methods: A sample of 366 AD patients was genotyped for ApoE. Subjects received tests of cognition (Mini-Mental State Examination, MMSE; Alzheimer’s Disease Assessment Scale-Cognitive subscale, ADAS-Cog) and daily function (Instrumental Activities of Daily Living, IADL; Alzheimer’s Disease Cooperative Study-Activities of Daily Living, ADCS-ADL) at baseline and at multiple subsequent time points during their participation in a variety of research protocols. In retrospective analyses, scores on baseline cognitive and functional measures were compared cross-sectionally among genotype groups, controlling for duration of symptoms. In prospective analyses, longitudinal rates of change for each measure were computed by linear regression and compared across genotype groups. Results: No association was observed between ApoE ε4 dose and any of the retrospective or prospective measures of cognitive or functional decline in this AD patient sample. Conclusions: Although ApoE ε4 increases the risk for AD and decreases the age of disease onset in population studies, it did not significantly influence the rate of disease progression in cognitive or functional domains in our sample.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Saunders AM, Strittmatter WJ, Schmechel DE, St George-Hyslop PH, Pericak-Vance MA, Joo BS, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
  2. Martins RN, Clarnette R, Fisher C, Broe GA, Brooks WS, Montgomery P, Gandy SE: ApoE genotypes in Australia: roles in early and late onset Alzheimer’s disease and Down syndrome. Neuroreport 1995;6:1513–1516.
  3. Utermann G, Langenbeck U, Beisiegel U, Weber W: Genetics of the apolipoprotein E system in man. Am J Hum Genet 1980;32:339–347.
  4. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  5. Farrer LA, Cupples LA, Haines JL, Hyman BT, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch NJ, van Duijn CM: Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease – a meta-analysis. JAMA 1997;278:1349–1356.
  6. Talbot C, Lendon CL, Craddock N, Shears S, Morris JC, Goate A: Protection against Alzheimer’s disease with apoE ε2. Lancet 1994;343:1432–1433.
  7. Nagy NS, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD: Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer’s disease. Neuroscience 1995;69:757–761.
  8. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, Perls TT, Lipsitz LA, Hyman BT: Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer’s disease. Ann Neurol 1996;39:62–70.
  9. Schmechel DE, Saunders AM, Strittmatter WJ, Crain B, Hulette C, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid β-peptide deposition as a consequence of apolipoprotein E genotype in late-onset Alzheimer’s disease. Proc Natl Acad Sci USA 1993;90:9649–9653.
  10. Norrman J, Brookes AJ, Yates C, St Clair D: Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer’s disease. Br J Psychiatry 1995;167:533–536.
  11. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL: Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology 2003;60:246–252.
  12. Higgins GA, Large CH, Rupniak HT, Barnes JC: Apolipoprotein E and Alzheimer’s disease: a review of recent studies. Pharmacol Biochem Behav 1997;56:675–685.
  13. Puglielli L, Tanzi RE, Kovacs DM: Alzheimer’s disease: the cholesterol connection. Nat Neurosci 2003;6:345–351.
  14. Strittmatter WJ, Saunders AM, Schmechel DE, Pericak-Vance MA, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
  15. Munson GW, Roher AE, Kuo YM, Gilligan SM, Reardon CA, Getz GS, Ladu MJ: SDS-stable complex formation between native apoliproprotein ε3 and β-amyloid peptides. Biochemistry 2000;39:16119–16124.
  16. Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer’s disease. Annu Rev Neurosci 1996;19:53–77.
  17. Basun H, Grut M, Winblad B, Lannfelt L: Apolipoprotein ε4 allele and disease progression in patients with late-onset Alzheimer’s disease. Neurosci Lett 1995;183:32–34.
  18. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A: ApoE ε4 allele and cognitive decline in patients with Alzheimer’s disease. Neurology 1996;47:603.
  19. Dal Forno G, Rasmusson X, Brandt J, Carson KA, Brookmeyer R, Troncoso J, Kawas CH: Apolipoprotein E genotype and rate of decline in probable Alzheimer’s disease. Arch Neurol 1996;53:345–350.
  20. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT: Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer’s disease. Neurology 1996;47:444–448.
  21. Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S: Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1996;61:580–583.
  22. Kurz A, Egensperger R, Haupt M, Lautenschlager N, Romero B, Graeber MB, Müller U: Apolipoprotein E ε4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer’s disease. Neurology 1996;47:440–443.
  23. Murphy GM, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR: No association between apolipoprotein E ε4 allele and rate of decline in Alzheimer’s disease. Am J Psychiatry 1997;154:603–608.
  24. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ: Association between apolipoprotein E ε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998;55:1065–1069.
  25. Lehtovirta M, Kuikka J, Helisalmi S, Hartikainen P, Mannermaa A, Ryynänen M, Riekkinen P Sr, Soininen H: Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998;64:742–746.
  26. Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B: Metrifonate treatment of AD – influence of APOE genotype. Neurology 1999;53:2010–2016.
  27. Slooter AJC, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, van Broeckhoven C, Breteler MMB, Hofman A, Stijnen T, van Duijn CM: Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam study. J Neurol 1999;246:304–308.
  28. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W: APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001;12:69–77.
  29. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, Matsui M: Accelerated hippocampal atrophy in Alzheimer’s disease with apolipoprotein E ε4 allele. Ann Neurol 2002;51:209–214.
  30. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB: Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer’s disease. Neurology 1998;51:149–153.
  31. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M: Apolipoprotein ε4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer’s disease. Neurosci Lett 1999;267:65–68.
  32. Hirono N, Hashimoto M, Yasuda M, Kazui H, Mori E: Accelerated memory decline in Alzheimer’s disease with apolipoprotein ε4 allele. J Neuropsychiatry Clin Neurosci 2003;15:354–358.
  33. Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, Trabucchi M: Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer’s disease. Ann Neurol 1995;37:596–604.
  34. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, Marder K, Sano M, Albert S, Castenada CD, Bylsma F, Tycko B, Mayeux R: The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer’s disease. Ann Neurol 1997;41:615–620.
  35. Gutterman EM, Markowitz JS, Lewis B, Fillit H: Cost of Alzheimer’s disease and related dementia in managed-Medicare. J Am Geriatr Soc 1999;47:1065–1071.
  36. Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H: Predicting caregiver burden and depression in Alzheimer’s disease. J Gerontol B Psychol Sci Soc Sci 2000;55:S2–S13.
  37. Tekin S, Fairbanks LA, O’Connor S, Rosenberg S, Cummings JL: Activities of daily living in Alzheimer’s disease: neuropsychiatric, cognitive and medical illness influences. Am J Geriatr Psychiatry 2001;9:81–86.
  38. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL: Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:214–221.
  39. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
  40. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The consortium to establish a registry for Alzheimer’s disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
  41. Breitner JCS, Folstein MF: Familial Alzheimer’s disease: a prevalent disorder with specific clinical features. Psychol Med 1984;14:63–80.
  42. Silverman JM, Breitner JCS, Mohs RC, Davis KL: Reliability of the family history method in genetic studies of Alzheimer’s disease and related dementias. Am J Psychiatry 1986;143:1279–1282.
  43. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  44. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  45. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–186.
  46. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:33–39.
  47. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–548.
  48. Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, Ivnik RJ, Thibodeau SN: Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994;54:643–649.
  49. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, Mannermaa A, Ryynänen M, Kuikka J, Hartikainen P, Riekkinen PJ: SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E ε4 allele. J Neurol Neurosurg Psychiatry 1996;60:644–649.
  50. Geroldi C, Pihlajamäki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB: APOE-ε4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825–1832.
  51. Van Dyck CH: Neuroimaging in Alzheimer’s disease: relevance for treatment. Curr Psychiatry Rep 2001;3:13–19.
  52. Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH: Apolipoprotein E ε4 is associated with atrophy of the amygdala in Alzheimer’s disease. Neurobiol Aging 2005, in press.
  53. Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, Hanninen T, Ryynänen M, Riekkinen P Sr: Clinical and neuropsychological characteristics in familial and sporadic Alzheimer’s disease: relation to apolipoprotein E polymorphism. Neurology 1996;46:413–419.
  54. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PCJ, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Tanzi RE, et al: Apolipoprotein E, survival in Alzheimer’s disease patients, and the competing risks of death and Alzheimer’s disease. Neurology 1995;45:1323–1328.
  55. Plassman BL, Breitner JCS: Apolipoprotein E and cognitive decline in Alzheimer’s disease. Neurology 1996;47:317–320.
  56. Chapman J, Korezyn AD, Karussis DM, Michaelson DM: The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology 2001;57:1482–1485.
  57. Roses AD: Apolipoprotein E alleles as risk factors in Alzheimer disease. Annu Rev Med 1996;47:387–400.
  58. Geschwind D, Karrim J, Nelson SF, Miller B: The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementia. Ann Neurol 1998;44:134–138.
  59. Nielsen AS, Ravid R, Kamphorst W, Jorgensen OS: Apolipoprotein E ε4 in an autopsy series of various dementing disorders. J Alzheimers Dis 2003;5:119–125.
  60. Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D: Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005;65:397–403.
  61. Van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden M, Okereke O, Varma P, Sei- byl JP, Hoffer PB: The absence of an apolipoprotein E ε4 allele is associated with increased parietal rCBF asymmetry in Alzheimer’s disease. Arch Neurol 1998;55:1460–1466.
  62. Kokmen E, Ozsarfati Y, Beard CM, O’Brien PC, Rocca WA: Impact of referral bias on clinical and epidemiological studies of Alzheimer’s disease. J Clin Epidemiol 1996;49:79–83.
  63. Watson JS, Matsuyama SS, Dirham PM, Liston EH, La Rue A, Jarvik LF: Relatives’ descriptions of changes in symptoms of dementia of the Alzheimer type: a comparison of retrospective and concurrent ratings. Alzheimer Dis Assoc Disord 1987;1:98–102.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50